a year ago

Infinitopes Secures £12.8M Seed Funding to Advance Cancer Vaccine Development

  • Infinitopes, an Oxford-based cancer biotech company, has raised £12.8M in Seed funding led by Octopus Ventures

  • The funding will be used to accelerate the installation of LC-MS/MS mass spectrometer equipment, enhancing their proprietary tumor antigen discovery and computational immunobiology/AI/machine learning techniques to identify and rank the best target combinations to treat five more cancers

  • Infinitopes combines precision antigen discovery with high efficiency vector delivery systems to develop immunologically durable vaccines for multiple solid tumour indications

  • Their lead vaccine candidate, ITOP1, is expected to begin phase I/IIa trials in Q3 2024.

      • ProblemHealthcare

      "making cancer treatment more effective and transformative for patients"

      Solution

      "developing precision targeted, durable cancer vaccines using proprietary tumour antigen discovery technologies and high-efficiency vector delivery systems"

      Covered on